NCI-Led Randomized Phase 2 Trial Design

The Phase 2, randomized clinical trial (NCT05001880, Alliance A092001), sponsored by the National Cancer Institute (NCI) and conducted by the Alliance for Clinical Trials in Oncology, is designed for patients with newly diagnosed peritoneal mesothelioma. Led by Dr. Hedy Lee Kindler, Director of the Mesothelioma Program at the University of Chicago, the trial aims to enroll a total of 62 patients (31 per arm). The control arm will receive carboplatin + pemetrexed (Alimta) + bevacizumab (Avastin), a three-drug regimen, while the experimental arm will receive the same regimen plus atezolizumab (Tecentriq), a four-drug regimen, followed by cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC).

Key Drugs and Mechanism of Action

Tecentriq (atezolizumab) is a PD-L1 immune checkpoint inhibitor developed by Roche/Genentech (ROG.SW). It works by binding to PD-L1 on tumor cells, restoring the ability of immune T cells to recognize and kill cancer cells. Avastin (bevacizumab) is another Roche product, a VEGF inhibitor that blocks tumor angiogenesis. Carboplatin and pemetrexed are platinum-based and antifolate chemotherapeutic agents that inhibit DNA synthesis. The rationale for the combination therapy is based on preclinical data suggesting that chemotherapy, by destroying cancer cells and increasing antigen exposure, can synergize with PD-L1 inhibitors.

Prior Data and Competitive Landscape

A previous Phase 2 study conducted by the same research group showed that the combination of atezolizumab and bevacizumab achieved an objective response rate (ORR) of 40%, a 1-year overall survival (OS) rate of 86%, and a median duration of response (DOR) of 12.8 months in patients with recurrent peritoneal mesothelioma. However, in a Phase 3 trial (BEAT-meso, ETOP 13-18, 400 patients) of the same four-drug regimen in patients with malignant pleural mesothelioma, the primary endpoint of OS was not significantly improved, and benefit was only observed in the non-epithelioid subtype. These results were reported in January 2025 in Annals of Oncology. Meanwhile, Bristol-Myers Squibb's (BMY) Opdivo (nivolumab) + Yervoy (ipilimumab) received FDA approval in October 2020 for the first-line treatment of unresectable malignant pleural mesothelioma (CheckMate 743, mOS 18.1 vs 14.1 months, HR 0.74), establishing it as the current standard of care in this setting.

Market Size and Investment Implications

The global market for malignant mesothelioma treatments is projected to grow from approximately $700 million (USD) in 2025 to $1.5 billion in 2035, with a compound annual growth rate of 7.8%. Peritoneal mesothelioma accounts for approximately 20% of this market (approximately $140 million). While the 5-year survival rate for peritoneal mesothelioma is relatively better than that for pleural mesothelioma (47-65%) when CRS/HIPEC is performed, there is still an unmet need for systemic treatment options. Due to the rare nature of the indication, the study is designed with a small sample size of 62 patients, providing 80% power to detect an improvement in response rate from 20% to 45% (one-sided α=0.10). Positive results could lead to a Phase 3 trial and a re-evaluation of Roche's mesothelioma portfolio.

Risks and Key Considerations

A key question is whether the failure of the BEAT-meso Phase 3 trial in malignant pleural mesothelioma is specific to that type of mesothelioma, or whether it reflects a limitation of the combination of immune checkpoint inhibitors and anti-angiogenic agents. Peritoneal mesothelioma has a different molecular profile than pleural mesothelioma, and the sequential strategy with CRS/HIPEC is also different, so it needs to be evaluated separately. The emergence of next-generation competitors, such as BioNTech's BNT327 (a PD-L1/VEGF-A bispecific antibody), is also a factor to monitor.